Health Care • Biotechnology: Pharmaceutical Preparations
$1.98 ▲ +0.01
(+0.51%)
MKT CAP: $21.5M • VOL: 9.5K
52W L $2 52W H $3
ROARABLE / RQD
D- • 41/100
PIOTROSKI
5 / 9
AYTU // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $66.4M | $65.2M | $107.4M |
| YoY Revenue Growth % | +1.8% | -39.3% | — |
| Gross Profit | $45.8M | $49.1M | — |
| Gross Margin % | 69.0% | 75.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.8M | -$1.6M | -$17.1M |
| Operating Margin % | -11.8% | -2.4% | -15.9% |
| Net Income (GAAP) | -$13.6M | -$15.8M | -$17.1M |
| EBITDA (Normalized) | -$7.6M | -$1.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.9M | -$1.4M | -$5.1M |
| Capital Expenditures (CapEx) | $228.0K | $329.0K | — |
| Free Cash Flow (FCF) | -$2.2M | -$1.7M | -$5.1M |
| FCF Margin % | -3.3% | -2.6% | -4.8% |
| Return on Invested Capital (ROIC %) | -45.0% | -6.2% | — |
| Cash & Short-Term Equivalents | $30.0M | $20.4M | — |
| Total Debt (Short + Long Term) | $10.0M | $10.0M | — |
| Total Stockholders' Equity | $14.2M | $30.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AYTU.